NanoRepro AG (ETR:NN6)

Market Cap	20.12M -7.3%
Revenue (ttm)	4.34M -3.0%
Net Income	-1.99M
EPS	-0.16
Shares Out	12.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.15 (9.40%)
Ex-Dividend Date	n/a

Volume	18,945
Open	1.550
Previous Close	1.610
Day's Range	1.550 - 1.700
52-Week Range	1.310 - 2.400
Beta	0.46
Analysts	Strong Buy
Price Target	4.45 (+179.0%)
Est. Earnings	Jun 7, 2027

About NanoRepro AG

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products. The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 22
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NN6

Financial Performance

In 2025, NanoRepro AG's revenue was 4.34 million, a decrease of -3.02% compared to the previous year's 4.47 million. Losses were -1.99 million, -2.87% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for NN6 stock is "Strong Buy." The 12-month stock price target is €4.45, which is an increase of 179.00% from the latest price.

Price Target

€4.45

(179.00% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error